Literature DB >> 28381479

Insulin Resistance Predicts Cognitive Decline: An 11-Year Follow-up of a Nationally Representative Adult Population Sample.

Laura L Ekblad1, Juha O Rinne2,3, Pauli Puukka4, Hanna Laine5,6, Satu Ahtiluoto7, Raimo Sulkava7, Matti Viitanen5,8, Antti Jula4.   

Abstract

OBJECTIVE: The aim of this study was to examine whether insulin resistance, assessed by HOMA of insulin resistance (HOMA-IR), is an independent predictor of cognitive decline. RESEARCH DESIGN AND METHODS: The roles of HOMA-IR, fasting insulin and glucose, HbA1c, and hs-CRP as predictors of cognitive performance and its change were evaluated in the Finnish nationwide, population-based Health 2000 Health Examination Survey and its 11-year follow-up, the Health 2011 study (n = 3,695, mean age at baseline 49.3 years, 55.5% women). Categorical verbal fluency, word-list learning, and word-list delayed recall were used as measures of cognitive function. Multivariate linear regression analysis was performed and adjusted for previously reported risk factors for cognitive decline.
RESULTS: Higher baseline HOMA-IR and fasting insulin levels were independent predictors of poorer verbal fluency performance (P = 0.0002 for both) and of a greater decline in verbal fluency during the follow-up time (P = 0.004 for both). Baseline HOMA-IR and insulin did not predict word-list learning or word-list delayed recall scores. There were no interactions between HOMA-IR and apolipoprotein E ε4 (APOEε4) genotype, hs-CRP, or type 2 diabetes on the cognitive tests. Fasting glucose and hs-CRP levels at baseline were not associated with cognitive functioning.
CONCLUSIONS: Our results show that higher serum fasting insulin and insulin resistance predict poorer verbal fluency and a steeper decline in verbal fluency during 11 years in a representative sample of an adult population. Prevention and treatment of insulin resistance might help reduce cognitive decline later in life.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28381479     DOI: 10.2337/dc16-2001

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  45 in total

1.  The chicken or the egg? Does glycaemic control predict cognitive function or the other way around?

Authors:  Ithamar Ganmore; Michal Schnaider Beeri
Journal:  Diabetologia       Date:  2018-07-12       Impact factor: 10.122

Review 2.  Cognition, Brain Structure, and Brain Function in Individuals with Obesity and Related Disorders.

Authors:  Hirofumi Tanaka; Drew D Gourley; Maria Dekhtyar; Andreana P Haley
Journal:  Curr Obes Rep       Date:  2020-10-16

Review 3.  Impaired insulin signalling and allostatic load in Alzheimer disease.

Authors:  Fernanda G De Felice; Rafaella A Gonçalves; Sergio T Ferreira
Journal:  Nat Rev Neurosci       Date:  2022-02-28       Impact factor: 34.870

4.  Brain effect of bariatric surgery in people with obesity.

Authors:  Angela Dardano; Gayane Aghakhanyan; Carlo Moretto; Annamaria Ciccarone; Rosario Bellini; Veronica Sancho Bornez; Giovanni Ceccarini; Ferruccio Santini; Duccio Volterrani; Stefano Del Prato; Giuseppe Daniele
Journal:  Int J Obes (Lond)       Date:  2022-06-21       Impact factor: 5.551

5.  The effectiveness of diet intervention in improving the metabolism of overweight and obese women: a systematic review and meta-analysis.

Authors:  Mengkun Chen; Qiuli Chen; Wenjun Liu; Hui Tong; Yuedan Wu
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

Review 6.  Overnutrition Induced Cognitive Impairment: Insulin Resistance, Gut-Brain Axis, and Neuroinflammation.

Authors:  Qin Zhang; Kangyu Jin; Bing Chen; Ripeng Liu; Shangping Cheng; Yuyan Zhang; Jing Lu
Journal:  Front Neurosci       Date:  2022-07-06       Impact factor: 5.152

Review 7.  Reassessment of Pioglitazone for Alzheimer's Disease.

Authors:  Ann M Saunders; Daniel K Burns; William Kirby Gottschalk
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

8.  Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study.

Authors:  Francesco Vadini; Paola G Simeone; Andrea Boccatonda; Maria T Guagnano; Rossella Liani; Romina Tripaldi; Augusto Di Castelnuovo; Francesco Cipollone; Agostino Consoli; Francesca Santilli
Journal:  Int J Obes (Lond)       Date:  2020-01-21       Impact factor: 5.095

Review 9.  Repurposing of Anti-Diabetic Agents as a New Opportunity to Alleviate Cognitive Impairment in Neurodegenerative and Neuropsychiatric Disorders.

Authors:  Qian Chen; Ting Cao; NaNa Li; Cuirong Zeng; Shuangyang Zhang; Xiangxin Wu; Bikui Zhang; Hualin Cai
Journal:  Front Pharmacol       Date:  2021-05-24       Impact factor: 5.810

10.  Incident Impaired Cognitive Function in Sarcopenic Obesity: Data From the National Health and Aging Trends Survey.

Authors:  John A Batsis; Christian Haudenschild; Robert M Roth; Tyler L Gooding; Meredith N Roderka; Travis Masterson; John Brand; Matthew C Lohman; Todd A Mackenzie
Journal:  J Am Med Dir Assoc       Date:  2020-10-21       Impact factor: 4.669

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.